Kura Oncology, Inc. (NASDAQ:KURA) Receives $25.46 Average PT from Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has been assigned a consensus rating of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $25.4615.

Several research analysts recently issued reports on KURA shares. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. Lake Street Capital assumed coverage on Kura Oncology in a report on Tuesday, April 14th. They set a “buy” rating and a $23.00 price objective on the stock. Mizuho lowered their price objective on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 24th. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a report on Monday, June 15th. Finally, Jefferies Financial Group set a $24.00 target price on Kura Oncology in a research report on Thursday, May 28th.

Kura Oncology Stock Up 8.6%

KURA opened at $11.99 on Friday. The company has a market capitalization of $1.06 billion, a P/E ratio of -3.58 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. The firm’s fifty day moving average price is $9.81 and its two-hundred day moving average price is $9.22. Kura Oncology has a fifty-two week low of $5.45 and a fifty-two week high of $12.49.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. The company had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. On average, analysts anticipate that Kura Oncology will post -3.45 EPS for the current year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the transaction, the insider directly owned 182,345 shares in the company, valued at $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently made changes to their positions in the company. IFP Advisors Inc boosted its position in Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after buying an additional 1,284 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Kura Oncology by 392.8% during the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after buying an additional 3,072 shares in the last quarter. Allworth Financial LP raised its stake in shares of Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after acquiring an additional 1,553 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after acquiring an additional 3,769 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after acquiring an additional 9,958 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.